Vicept Therapeutics Incorporated Announces Positive Phase II Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea)
1/10/2011 9:11:53 AM
(BUSINESS WIRE)--Vicept Therapeutics, Inc. announced today positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significant (p=0.0006) improvement in the primary end point, which was a reduction in facial erythema, over an eight hour period in patients with erythematotelangiectatic rosacea (ETR), versus placebo. Further, V-101 demonstrated a safety profile similar to placebo cream and no evidence of “rebound” or tachyphylaxis was observed.